Why it matters now
Geopolitical tensions are driving increased scrutiny of global supply chains, particularly in critical sectors like pharmaceuticals. Governments are prioritizing domestic capabilities and diversifying sourcing to reduce reliance on specific regions. This shift impacts the operational strategies and risk profiles of pharmaceutical companies that have historically leveraged global manufacturing networks. The evolving regulatory landscape and calls for greater supply chain transparency add urgency for businesses to assess their vulnerabilities and adapt their strategies to maintain continuity and compliance.
Who is exposed
US pharmaceutical companies face potential disruptions to their manufacturing processes, impacting revenue streams if key drug components or finished products are delayed or unavailable. Contract development manufacturing organizations (CDMOs) with significant operations in China or serving US clients may see shifts in demand and increased compliance burdens. R&D functions might experience delays in clinical trial material production. Overall, companies must evaluate their entire supply chain for potential cost increases and compliance risks.
Most relevant for: Chief Procurement Officer, Head of Supply Chain, Government Affairs
What this Viewpoint covers
- Which US pharma products rely on Chinese CDMOs for active pharmaceutical ingredients or finished drug products?
- How are recent policy changes in the US and China impacting CDMO operations and partnerships?
- What alternatives are emerging for pharmaceutical manufacturing outside of China?
- Which types of CDMO services are most susceptible to geopolitical shifts?
- How do regulatory approval pathways differ for products manufactured in various regions?
Signals to watch
- New government directives regarding pharmaceutical supply chain origins
- Announcements of major pharmaceutical manufacturing investments in new regions
- Changes in trade policies affecting pharmaceutical intermediates or finished products
- Public statements from pharmaceutical executives on supply chain diversification
Decisions it supports
- Diversify pharmaceutical manufacturing and sourcing strategies
- Assess and mitigate supply chain risks related to geopolitical factors
- Evaluate potential new CDMO partnerships and regional manufacturing hubs
How it is built
Prepared after your order from dated public sources - such as pharma & biotech filings and announcements, regulatory records, trials, patents and trade data, where relevant - and our market model. Reported facts are cited, estimates are labelled and our assessment is marked as such, following our research method. You receive our verdict, the evidence, who is exposed, the signals to watch and recommended actions, within 24 hours.
Questions
What kind of restrictions are being considered for Chinese CDMOs?
Restrictions could include enhanced due diligence requirements, limitations on sourcing critical materials from specific regions, or incentives for domestic production. These measures aim to bolster national supply chain security and reduce dependency on foreign manufacturing for essential medicines. The focus is on ensuring a resilient and reliable supply of pharmaceuticals.
How quickly might these restrictions impact US pharma companies?
The impact could vary, with some changes taking effect over time as new policies are implemented and supply chains adjust. Companies with immediate dependencies might feel effects sooner. Strategic planning and proactive adaptation are crucial to navigate potential disruptions and ensure continued access to necessary manufacturing capabilities.
Does this Viewpoint provide recommendations for specific suppliers?
This Viewpoint focuses on the broader landscape of exposure and strategic considerations rather than endorsing specific suppliers. It provides an evidence-based framework to help companies understand their vulnerabilities and explore options. The aim is to equip leaders with insights to make informed decisions about their supply chain resilience and future sourcing strategies.